Area of research
Epidemiology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Opioid Use Disorder Treatment, Substance Abuse Treatment and Outcomes, HIV, Drug Use, Sexual Risk, and Pain Management and Opioid Use.
Culturally Engaged REcovery - MOms connected through Native CommunitY (CEREMONY): An Implementation Study to Evaluate the Adaptation and Implementation of an Integrated Perinatal SUD Clinical Model for Pregnant and Postpartum Native People.
The ELEVATE Maternal Health Center of Excellence: A Program to Reduce Maternal Morbidity From Substance Use Disorder in Utah.
Treatment of opioid use disorder in pregnancy among individuals with and without co-occurring stimulant use disorder: A retrospective cohort study.
Explaining Variation in VA Opioid Treatment Program Clinical Practice Following Regulatory Reform: A Qualitative Study.
Primary care provider attitudes regarding physical therapists addressing opioid use and opioid misuse: a qualitative study.
Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder
Changes in healthcare utilization and costs following enrollment in an interprofessional primary care clinic designed to address clinical and social vulnerabilities.
Quality Indicators for Pain in Adults.
The Roles, Activities, and Opportunities of Clinical Pharmacists in a National Initiative to Improve Office-Based Buprenorphine Care.
Promoting Health Equity Among People With Opioid Use Disorder and Serious Mental Illness Through the Chronic Disease Self-Management Program.
Factors associated with mortality following hospitalization among veterans with opioid use disorder.
Commentary With Study Protocol: Implementation and Effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) as an Adjunct to Methadone Treatment for Opioid Use Disorder (IMPOWR-MORE).
Development and validation of machine-learning algorithms predicting retention, overdoses, and all-cause mortality among US military veterans treated with buprenorphine for opioid use disorder.
Practice Changes 6 Months Following a Physical Therapist Training Program Regarding Opioid Use and Misuse Screening and Assessment: A Qualitative Study.
Post-hospitalization Care Transition Strategies for Patients with Substance Use Disorders: A Narrative Review and Taxonomy
Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization
Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies
A Systematic Review of State Office-Based Buprenorphine Treatment Laws Effective During 2022: Counseling, Dosage, and Visit Frequency Requirements
Medicare Payment for Opioid Treatment Programs
Design and development of a machine-learning-driven opioid overdose risk prediction tool integrated in electronic health records in primary care settings
Organizational and patient factors associated with positive primary care experiences for veterans with current or recent homelessness
Using the Delphi Process to Prioritize an Agenda for Care Transition Research for Patients With Substance Use Disorders.
Organizational and patient factors associated with positive primary care experiences for veterans with current or recent homelessness.
Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder.
Developing Evidence to Support Policy: Protocol for the StrAtegic PoLicy EvIdence-Based Evaluation CeNTer (SALIENT).
"They Ask Questions, But They Don't Want the Answers"-Perceptions of Clinical Communication Among Veterans Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.
A novel rural hospital/clinic-system practice-based research network: the Rural Addiction Implementation Network (RAIN) initiative and its goals, implementation, and early results.
Developing Evidence to Support Policy: Protocol for the StrAtegic PoLicy EvIdence-Based Evaluation CeNTer (SALIENT) (Preprint)
Comparative effectiveness of psychosocial interventions in adults with harmful use of alcohol: a systematic review and network meta‐analysis
Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act